The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above.

The latest move follows the recommendation for the Covid-19 vaccine to be used as an adult booster dose from the Korean Centers for Disease Control and Prevention in September last year.

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

It has been developed using the company’s recombinant nanoparticle technology.

The expanded manufacturing and marketing approval was based on the data obtained from the Phase II trial, conducted in Australia and the US; a separate Phase II trial held in South Africa; and the UK-sponsored COV-BOOST trial.

In the Phase II trials, adult participants received a single Nuvaxovid booster dose six months after their initial two-dose vaccine doses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials.

Nuvaxovid demonstrated a significant antibody response when given as a booster dose after primary vaccination with other authorised Covid-19 doses in the COV-BOOST trial.

In January 2022, the vaccine was approved by KFMDS as a primary series in adults aged 18 and above.

The regulator approved Nuvaxovid for use as a primary series in adolescents aged 12 to 17 years in August last year.

SK bioscience is manufacturing Nuvaxovid’s drug substance, and drug product for domestic use after the companies signed a licensing agreement in Korea.

Novavax president and CEO Stanley Erck said: “We are pleased to collaborate with SK bioscience to offer our protein-based vaccine, Nuvaxovid, for use as a booster in adults regardless of previous vaccine history.

“This is an important step in ensuring broad access to diversified vaccine options.”

The company stated that the vaccine has already been approved for use as an adult booster in over 35 nations, with many other countries having policy recommendations.